Financials
- Market Capitalization 25.44 B
- Employee 721
- Founded 2014
- CEO Matt Gline
- Website www.roivant.com
- Headquarter Bermuda
- FIGI N/A
- Industry Biyoteknoloji
Toplam gelir
Net kar
Temel hisse başına kazanç (Temel EPS)
Toplam borç
Serbest nakit akışı
Nakit ve eşdeğerleri
Fiyat/kazanç oranı
-51.3
Fiyat/satışlar oranı
2 326.88
Related tickers
| # | Ad | Fiyat | 24s % | 7g % | 1A % | 1Y % | Piyasa Değeri | Son 7 Gün | |
|---|---|---|---|---|---|---|---|---|---|
| 367 | RVMD Revolution Medicines, Inc. - Common Stock | 190.00 USD | +0.13% | -8.24% | -6.63% | +242.96% | 40.72 B USD | ||
| 434 | ALNY Alnylam Pharmaceuticals, Inc. - Common Stock | 229.90 USD | -1.19% | +5.66% | -8.10% | -49.60% | 30.76 B USD | ||
| 499 | RPRX Royalty Pharma plc - Class A Ordinary Shares | 57.20 USD | +0.47% | +0.58% | -2.49% | +53.52% | 25.54 B USD | ||
| 524 | UTHR United Therapeutics Corporation - Common Stock | 552.49 USD | +0.61% | +1.79% | +9.04% | +26.27% | 23.70 B USD |